Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review
At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2023-12-01
|
| Series: | Non-coding RNA Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468054023000367 |
| _version_ | 1797401691900870656 |
|---|---|
| author | Meity Ardiana Asiyah Nurul Fadila Zakirah Zuhra Nabilla Merdika Kusuma Made Edgard Surya Erlangga Rurus Delvac Oceandy |
| author_facet | Meity Ardiana Asiyah Nurul Fadila Zakirah Zuhra Nabilla Merdika Kusuma Made Edgard Surya Erlangga Rurus Delvac Oceandy |
| author_sort | Meity Ardiana |
| collection | DOAJ |
| description | At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation. |
| first_indexed | 2024-03-09T02:13:42Z |
| format | Article |
| id | doaj.art-6bcafa68f9cc415d80c26f4076f5556f |
| institution | Directory Open Access Journal |
| issn | 2468-0540 |
| language | English |
| last_indexed | 2024-03-09T02:13:42Z |
| publishDate | 2023-12-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Non-coding RNA Research |
| spelling | doaj.art-6bcafa68f9cc415d80c26f4076f5556f2023-12-07T05:29:51ZengKeAi Communications Co., Ltd.Non-coding RNA Research2468-05402023-12-0184487506Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic reviewMeity Ardiana0Asiyah Nurul Fadila1Zakirah Zuhra2Nabilla Merdika Kusuma3Made Edgard Surya Erlangga Rurus4Delvac Oceandy5Department of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia; Faculty of Medicine, Airlangga University, Surabaya, Indonesia; Corresponding author. Department of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia.Department of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia; Faculty of Medicine, Airlangga University, Surabaya, IndonesiaDepartment of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia; Faculty of Medicine, Airlangga University, Surabaya, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, Hang Tuah University, Surabaya, IndonesiaDivision of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United KingdomAt present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.http://www.sciencedirect.com/science/article/pii/S2468054023000367Non-coding RNARNA therapeuticsCardiovascular diseasesCardiovascular risk factorsCardiogenetics |
| spellingShingle | Meity Ardiana Asiyah Nurul Fadila Zakirah Zuhra Nabilla Merdika Kusuma Made Edgard Surya Erlangga Rurus Delvac Oceandy Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review Non-coding RNA Research Non-coding RNA RNA therapeutics Cardiovascular diseases Cardiovascular risk factors Cardiogenetics |
| title | Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review |
| title_full | Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review |
| title_fullStr | Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review |
| title_full_unstemmed | Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review |
| title_short | Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review |
| title_sort | non coding rna therapeutics in cardiovascular diseases and risk factors systematic review |
| topic | Non-coding RNA RNA therapeutics Cardiovascular diseases Cardiovascular risk factors Cardiogenetics |
| url | http://www.sciencedirect.com/science/article/pii/S2468054023000367 |
| work_keys_str_mv | AT meityardiana noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview AT asiyahnurulfadila noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview AT zakirahzuhra noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview AT nabillamerdikakusuma noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview AT madeedgardsuryaerlanggarurus noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview AT delvacoceandy noncodingrnatherapeuticsincardiovasculardiseasesandriskfactorssystematicreview |